– USA, MA – Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the Board of Directors has elected Bruce L.A. Carter, Ph.D. as non-executive Chairman of the Board. Dr. Carter has been an independent director of Enanta since November 2013. He currently serves as the Chair of the Compensation Committee and is a member of the Nominating and Corporate Governance Committee.
“Since his appointment in 2013, Bruce has used his extensive industry experience to provide great judgment and strong leadership to the Enanta Board. We look forward to his continuing leadership in his new role at Enanta,” stated Jay R. Luly, Ph.D., President and Chief Executive Officer.
Dr. Carter has extensive experience in the pharmaceutical and biotechnology industries, having served as Corporate Executive Vice President and Chief Scientific Officer of Novo Nordisk and as an executive in research at ZymoGenetics and G.D.Searle. Dr. Carter was the President and CEO of ZymoGenetics until 2009, and served most recently as the Executive Chairman of Immune Design Corp. until 2011. He has served as a director of several biotechnology companies, including as non-executive Chairman of the Board of ZymoGenetics when it was sold to Bristol-Myers Squibb in 2010, and currently serves as a director of Dr. Reddy’s Laboratories and Xencor, Inc. Dr. Carter is also an Affiliate Professor, Department of Biochemistry at the University of Washington, Seattle, Washington and serves as Board Chair of the Infectious Disease Research Institute in Seattle, Washington and is on the Board of Directors of the TB Alliance.
Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta has developed novel protease and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta’s protease inhibitors partnered with AbbVie include paritaprevir, which is contained in AbbVie’s marketed DAA regimens for HCV, and ABT-493, Enanta’s next-generation protease inhibitor which AbbVie is developing in phase 3 studies in combination with ABT-530, AbbVie’s next-generation NS5A inhibitor. Enanta also has discovered EDP-494, a host-targeted antiviral (HTA) inhibitor for HCV targeted against cyclophilin, which Enanta plans to study in a phase 1 clinical trial in the first quarter of 2016. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and liver damage caused by a buildup of fat in the liver.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.